Sledovať
Jean-Christophe Pignon
Jean-Christophe Pignon
Principal Scientist
Overená e-mailová adresa na: jouncetx.com
Názov
Citované v
Citované v
Rok
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
B Li, E Severson, JC Pignon, H Zhao, T Li, J Novak, P Jiang, H Shen, ...
Genome biology 17, 1-16, 2016
19562016
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
DA Braun, Y Hou, Z Bakouny, M Ficial, M Sant’Angelo, J Forman, ...
Nature medicine 26 (6), 909-918, 2020
6142020
Landscape of tumor-infiltrating T cell repertoire of human cancers
B Li, T Li, JC Pignon, B Wang, J Wang, SA Shukla, R Dou, Q Chen, ...
Nature genetics 48 (7), 725-732, 2016
3082016
p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia
JC Pignon, C Grisanzio, Y Geng, J Song, RA Shivdasani, S Signoretti
Proceedings of the National Academy of Sciences 110 (20), 8105-8110, 2013
2412013
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma
DJ Kwiatkowski, TK Choueiri, AP Fay, BI Rini, AR Thorner, G De Velasco, ...
Clinical Cancer Research 22 (10), 2445-2452, 2016
2162016
Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
NM Tannir, S Signoretti, TK Choueiri, DF McDermott, RJ Motzer, A Flaifel, ...
Clinical Cancer Research 27 (1), 78-86, 2021
1962021
irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial
JC Pignon, O Jegede, SA Shukla, DA Braun, CE Horak, M Wind-Rotolo, ...
Clinical Cancer Research 25 (7), 2174-2184, 2019
932019
Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines
JC Pignon, B Koopmansch, G Nolens, L Delacroix, D Waltregny, ...
Cancer research 69 (7), 2941-2949, 2009
902009
KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1
RS Bhatt, A Berjis, JC Konge, KM Mahoney, AN Klee, SS Freeman, ...
Cancer immunology research 9 (2), 156-169, 2021
812021
Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma
M Ficial, OA Jegede, M Sant'Angelo, Y Hou, A Flaifel, JC Pignon, ...
Clinical Cancer Research 27 (5), 1371-1380, 2021
542021
Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2overexpression in breast cancer cell lines
G Nolens, JC Pignon, B Koopmansch, B Elmoualij, W Zorzi, E De Pauw, ...
Breast Cancer Research 11, 1-11, 2009
322009
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
AKA Lalani, KP Gray, L Albiges, M Callea, JC Pignon, S Pal, M Gupta, ...
Oncotarget 8 (61), 103428, 2017
232017
Young investigator challenge: application of cytologic techniques to circulating tumor cell specimens: detecting activation of the oncogenic transcription factor STAT3
AC Lowe, JC Pignon, I Carvo, MG Drage, NM Constantine, N Jones, ...
Cancer Cytopathology 123 (12), 696-706, 2015
212015
p63+ ureteric bud tip cells are progenitors of intercalated cells
SS El-Dahr, Y Li, J Liu, E Gutierrez, KS Hering-Smith, S Signoretti, ...
JCI insight 2 (9), 2017
182017
ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity
K Uchida, H Ross, T Lotan, JC Pignon, S Signoretti, JI Epstein, PB Illei
Human pathology 46 (3), 384-389, 2015
182015
Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma
T Denize, Y Hou, JC Pignon, E Walton, DJ West, GJ Freeman, DA Braun, ...
Clinical Cancer Research 28 (18), 4045-4055, 2022
172022
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
L Hamieh, TK Choueiri, B Ogórek, D Khabibullin, D Rosebrock, D Livitz, ...
PLoS genetics 14 (9), e1007679, 2018
162018
Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell …
JC Pignon, O Jegede, KM Mahoney, RB Moreira, J Novak, H Conen, ...
Journal of Clinical Oncology 35 (6_suppl), 477-477, 2017
102017
Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.
M Ficial, O Jegede, M Sant'Angelo, S Moreno, DA Braun, M Wind-Rotolo, ...
Journal of Clinical Oncology 38 (15_suppl), 5023-5023, 2020
92020
Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).
JC Pignon, O Jegede, SA Shukla, DA Braun, C Horak, M Wind-Rotolo, ...
Journal of Clinical Oncology 37 (15_suppl), 4568-4568, 2019
82019
Systém momentálne nemôže vykonať operáciu. Skúste to neskôr.
Články 1–20